Navigation Links
CVS Caremark Reports Record Second Quarter Results
Date:8/6/2013

WOONSOCKET, R.I., Aug. 6, 2013 /PRNewswire/ -- CVS Caremark Corporation (NYSE: CVS) today announced operating results for the three months ended June 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

Second Quarter Year-over-year Highlights:

  • Operating profit increased 15.2% to approximately $2.0 billion
  • Adjusted EPS increased 19.6% to $0.97; GAAP diluted EPS from continuing operations increased 20.8% to $0.91
  • Retail pharmacy same store prescription volumes increased 1.8%, or 5.0% on a 30-day equivalent basis
  • Retail pharmacy same store sales increased 0.8%; total same store sales increased 0.4%
  • Year-to-date Highlights:

  • Generated free cash flow of $1.7 billion
  • Cash flow from operations of $2.5 billion
  • 2013 Guidance:

  • Narrowed 2013 full-year Adjusted EPS range to $3.90 to $3.96 and GAAP diluted EPS from continuing operations range to $3.65 to $3.71
  • Provided third quarter Adjusted EPS guidance of $1.00 to $1.03 and GAAP diluted EPS from continuing operations guidance of $0.94 to $0.97
  • Expect full year free cash flow of $4.8 to $5.1 billion and cash flow from operations of $6.4 to $6.6 billion
  • RevenuesNet revenues for the three months ended June 30, 2013, increased 1.7%, or $534 million, compared to the three months ended June 30, 2012.

    Revenues in the Pharmacy Services Segment increased 2.0%, or $377 million, in the three months ended June 30, 2013. The growth was primarily driven by volume increases across all channels and drug cost inflation in our specialty pharmacy business, partially offset by the impact of new generic introductions. Pharmacy network claims processed during the three months ended June 30, 2013, increased 4.1% to 205.9 million, compared to 197.8 million in the prior year period. The increase in pharmacy network claims was primarily due to additional claims activity associated with new clients. Mail choice claims processed during the three months ended June 30, 2013, increased approximately 1.0% to 20.7 million, compared to 20.5 million in the prior year period. The increase in the mail choice claim volume was primarily due to increased claims associated with the continuing adoption of our Maintenance Choice® offerings.

    Revenues in the Retail Pharmacy Segment increased 1.9%, or $293 million, in the three months ended June 30, 2013. Same store sales increased 0.4% when compared to the prior year period, with pharmacy same store sales up 0.8% and front store same store sales down 0.4%. The increase in same store sales was primarily driven by same store prescription volumes, partially offset by new generic drug introductions and the shift of the Easter holiday from April in 2012 to March in 2013. Pharmacy same store prescription volumes rose 1.8% when 90-day prescriptions are counted as one prescription. On a 30-day equivalent basis, same store prescription volumes increased 5.0% in the quarter. Pharmacy same store sales were negatively impacted by approximately 670 basis points due to recent generic introductions. Front store same store sales were negatively impacted by approximately 65 basis points due to the shift of the Easter holiday.

    For the three months ended June 30, 2013, the generic dispensing rate increased approximately 270 basis points in our Pharmacy Services Segment, to 80.7%, and approximately 280 basis points in our Retail Pharmacy Segment, to 81.9%, compared to the prior year period.

    Income from Continuing Operations Attributable to CVS CaremarkIncome from continuing operations attributable to CVS Caremark for the three months ended June 30, 2013, increased 15.9%, or approximately $154 million, to $1.1 billion, compared with $967 million during the three months ended June 30, 2012. The increase in income from continuing operations was primarily driven by the positive impact from new generics, which significantly improved operating profit in both our Pharmacy Services and Retail Pharmacy segments. Adjusted earnings per share from continuing operations attributable to CVS Caremark (Adjusted EPS) for the three months ended June 30, 2013 and 2012, was $0.97 and $0.81, respectively, an increase of 19.6%. Adjusted EPS excludes $124 million and $123 million of intangible asset amortization related to acquisition activity in the three months ended June 30, 2013, and 2012, respectively. GAAP earnings per diluted share from continuing operations attributable to CVS Caremark for the three months ended June 30, 2013, and 2012, was $0.91 and $0.75, respectively, an increase of 20.8%.

    President and Chief Executive Officer Larry Merlo said, "Our second quarter results reflect very strong operating performance, with operating profit increasing 15% enterprise-wide, with 32% growth in the PBM and 9% growth in the retail business. As expected, new generic drug introductions continued to be a significant growth driver across the enterprise, resulting in healthy margin expansion and earnings growth. We achieved Adjusted EPS for the quarter at the high end of our guidance range despite a higher-than-anticipated share count."

    Mr. Merlo continued, "A primary reason for our higher-than-anticipated share count is that we suspended share repurchases during part of the second quarter while we were engaged in negotiations with the SEC concerning the agreement in principle we announced last week. However, we remain committed to returning significant value to our shareholders through both dividends and share repurchases. We have delivered $1.7 billion in free cash flow year-to-date and we expect to complete our planned $4 billion in share repurchases during 2013."

    Real Estate ProgramDuring the three months ended June 30, 2013, the Company opened 23 new retail drugstores, and closed one retail drugstore and one retail specialty pharmacy store. In addition, the Company relocated 24 retail drugstores. As of June 30, 2013, the Company operated 7,617 locations in 45 states, the District of Columbia, Puerto Rico and Brazil. These locations included 7,553 retail drugstores, 18 onsite pharmacies, 30 retail specialty pharmacy stores, 12 specialty mail order pharmacies and four mail service pharmacies.

    GuidanceThe Company narrowed its earnings guidance range for the full year 2013, primarily to reflect the timing of share repurchases and strong operating results. The Company completed $355 million in share repurchases during the second quarter and $748 million year to date, which is less than originally anticipated. These 2013 guidance estimates assume the completion of approximately $4 billion in previously authorized share repurchases this year. However, with share repurchases back-half weighted as opposed to occurring ratably throughout the year as originally anticipated, this timing shift is estimated to dampen the accretive impact on the Company's EPS in 2013 by as much as 4 cents per share. The Company currently expects to deliver Adjusted EPS of $3.90 to $3.96 and GAAP diluted earnings per share from continuing operations of $3.65 to $3.71 per share in 2013. The Company expects to deliver 2013 free cash flow of $4.8 billion to $5.1 billion, and 2013 cash flow from operations guidance of $6.4 billion to $6.6 billion.

    Teleconference and WebcastThe Company will be holding a conference call today for the investment community at 8:30 am (EDT) to discuss its quarterly results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Caremark website at http://info.cvscaremark.com/investors. This webcast will be archived and available on the website for a one-year period following the conference call.

    About the CompanyCVS Caremark is dedicated to helping people on their path to better health as the largest integrated pharmacy company in the United States. Through the Company's more than 7,500 retail pharmacy stores; its leading pharmacy benefit manager serving more than 60 million plan members; and its retail health clinic system, the largest in the nation with more than 650 MinuteClinic® locations, it is a market leader in mail order, retail and specialty pharmacy, retail clinics, and Medicare Part D Prescription Drug Plans. As a pharmacy innovation company with an unmatched breath of capabilities, CVS Caremark continually strives to improve health and lower costs by developing new approaches such as its unique Pharmacy Advisor® program that helps people with chronic diseases such as diabetes obtain and stay on their medications. Find more information about how CVS Caremark is reinventing pharmacy for better health at http://info.cvscaremark.com/.

    Forward-Looking StatementsThis press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2012 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q.

    — Tables Follow —

     CVS CAREMARK CORPORATION Condensed Consolidated Statements of Income (Unaudited)Three Months EndedJune 30,Six Months EndedJune 30,In millions, except per share amounts2013201220132012Net revenues$

    31,248$

    30,714$

    62,011$

    61,512Cost of revenues25,41225,26550,59350,950Gross profit5,8365,44911,41810,562Operating expenses3,8683,7417,7517,451Operating profit1,9681,7083,6673,111Interest expense, net126132252263Income before income tax provision1,8421,5763,4152,848Income tax provision7206101,3371,106Income from continuing operations1,1229662,0781,742Loss from discontinued operations, net of tax(1)(1)(1)(2)Net income1,1219652,0771,740Net loss attributable to noncontrolling interest—1—2Net income attributable to CVS Caremark$

    1,121$

    966$

    2,077$

    1,742Income from continuing operations attributable to CVS Caremark:Income from continuing operations$

    1,121$

    966$

    2,077$

    1,742Net loss attributable to noncontrolling interest—1—2Income from continuing operations attributable to CVS Caremark$

    1,121$

    967$

    2,077$

    1,744Basic earnings per common share:Income from continuing operations attributable to CVS Caremark$

    0.91$

    0.76$

    1.69$

    1.35Loss from discontinued operations attributable to CVS Caremark————Net income attributable to CVS Caremark$

    0.91$

    0.76$

    1.69$

    1.35Weighted average basic common shares outstanding1,2271,2781,2301,289Diluted earnings per common share:Income from continuing operations attributable to CVS Caremark$

    0.91$

    0.75$

    1.68$

    1.34Loss from discontinued operations attributable to CVS Caremark————Net income attributable to CVS Caremark$

    0.91$

    0.75$

    1.68$

    1.34Weighted average diluted common shares outstanding1,2361,2871,2381,298Dividends declared per common share$

    0.2250$

    0.1625$

    0.4500$

    0.3250 CVS CAREMARK CORPORATION Condensed Consolidated Balance Sheets (Unaudited)June 30,December 31,In millions, except per share amounts20132012Assets:Cash and cash equivalents$

    1,174$

    1,375Short-term investments55Accounts receivable, net7,0936,473Inventories10,57810,759Deferred income taxes606663Other current assets413577Total current assets19,86919,852Property and equipment, net8,7088,632Goodwill26,55426,395Intangible assets, net9,6579,753Other assets1,4961,280Total assets$

    66,284$

    65,912Liabilities:Accounts payable$

    5,178$

    5,070Claims and discounts payable3,9933,974Accrued expenses3,5014,051Short-term debt—690Current portion of long-term debt185Total current liabilities12,69013,790Long-term debt9,3589,133Deferred income taxes3,7963,784Other long-term liabilities1,5341,501Commitments and contingencies——Shareholders' equity:Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding——Common stock, par value $0.01: 3,200 shares authorized; 1,676 shares issued and1,227 shares outstanding at June 30, 2013 and 1,667 shares issued and 1,231 sharesoutstanding at December 31, 20121717Treasury stock, at cost: 448 shares at June 30, 2013 and 435 shares at December 31,2012(16,987)(16,270)Shares held in trust: 1 share at June 30, 2013 and December 31, 2012(31)(31)Capital surplus29,53229,120Retained earnings26,57325,049Accumulated other comprehensive loss(198)(181)Total shareholders' equity38,90637,704Total liabilities and shareholders' equity$

    66,284$

    65,912 CVS CAREMARK CORPORATION Condensed Consolidated Statements of Cash Flows (Unaudited)Six Months EndedJune 30,In millions20132012Cash flows from operating activities:Cash receipts from customers$

    56,446$

    57,644Cash paid for inventory and prescriptions dispensed by retail network pharmacies(44,657)(45,289)Cash paid to other suppliers and employees(7,452)(7,134)Interest received21Interest paid(267)(281)Income taxes paid(1,530)(924)Net cash provided by operating activities2,5424,017Cash flows from investing activities:Purchases of property and equipment(804)(818)Proceeds from sale of property and equipment11—Acquisitions (net of cash acquired) and other investments(300)(274)Proceeds from sale of subsidiary—7Net cash used in investing activities(1,093)(1,085)Cash flows from financing activities:Decrease in short-term debt(690)(550)Repayments of long-term debt—(54)Purchase of noncontrolling interest in subsidiary—(26)Dividends paid(553)(420)Proceeds from exercise of stock options309518Excess tax benefits from stock-based compensation348Repurchase of common stock(748)(1,998)Net cash used in financing activities(1,648)(2,522)Effect of exchange rates on cash(2)—Net increase (decrease) in cash and cash equivalents(201)410Cash and cash equivalents at the beginning of the year1,3751,413Cash and cash equivalents at the end of the year$

    1,174$

    1,823Reconciliation of net income to net cash provided by operating activities:Net income$

    2,077$

    1,740Adjustments required to reconcile net income to net cash provided by operating activities:Depreciation and amortization951854Stock-based compensation6664Deferred income taxes and other non-cash items8283Change in operating assets and liabilities, net of effects of acquisitions:Accounts receivable, net(575)(13)Inventories204(527)Other current assets165254Other assets(138)(181)Accounts payable and claims and discounts payable98655Accrued expenses(412)1,095Other long-term liabilities24(7)Net cash provided by operating activities$

    2,542$

    4,017 Adjusted Earnings Per Share (Unaudited)For internal comparisons, management finds it useful to assess year-over-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.The Company defines adjusted earnings per share as income before income tax provision plus amortization, less adjusted income tax provision, plus net loss attributable to noncontrolling interest divided by the weighted average diluted common shares outstanding.The following is a reconciliation of income before income tax provision to adjusted earnings per share:Three Months EndedJune 30,Six Months EndedJune 30,In millions, except per share amounts2013201220132012Income before income tax provision$

    1,842$

    1,576$

    3,415$

    2,848Amortization124123246241Adjusted income before income tax provision1,9661,6993,6613,089Adjusted income tax provision(1) 7696581,4331,199Adjusted income from continuing operations1,1971,0412,2281,890Net loss attributable to noncontrolling interest—1—2Adjusted income from continuing operations attributable toCVS Caremark$

    1,197$

    1,042$

    2,228$

    1,892Weighted average diluted common shares outstanding1,2361,2871,2381,298Adjusted earnings per share from continuing operationsattributable to CVS Caremark$

    0.97$

    0.81$

    1.80$

    1.46(1) The adjusted income tax provision is computed using the effective income tax rate from the consolidated statement of income. Free Cash Flow(Unaudited)The Company defines free cash flow as net cash provided by operating activities less net additions to properties and equipment (i.e., additions to property and equipment plus proceeds from sale-leaseback transactions).The following is a reconciliation of net cash provided by operating activities to free cash flow:Six Months EndedJune 30,In millions20132012Net cash provided by operating activities$

    2,542$

    4,017Subtract: Additions to property and equipment(804)(818)Free cash flow$

    1,738$

    3,199 Supplemental Information (Unaudited)The Company evaluates its Pharmacy Services and Retail Pharmacy Segment performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of the Company's segments to the accompanying consolidated financial statements:In millionsPharmacy ServicesSegment(1)Retail Pharmacy SegmentCorporate SegmentIntersegment Eliminations(2)ConsolidatedTotalsThree Months EndedJune 30, 2013:Net revenues$

    18,800$

    16,139$

    —$

    (3,691)$

    31,248Gross profit9635,000—(127)5,836Operating profit (loss)6751,596(176)(127)1,968June 30, 2012:Net revenues18,42315,846—(3,555)30,714Gross profit7774,769—(97)5,449Operating profit (loss)5111,469(175)(97)1,708Six Months EndedJune 30, 2013:Net revenues37,11132,191—(7,291)62,011Gross profit1,7319,952—(265)11,418Operating profit (loss)1,1743,133(375)(265)3,667June 30, 2012:Net revenues36,72231,869—(7,079)61,512Gross profit1,3939,341—(172)10,562Operating profit (loss)8602,766(343)(172)3,111Total Assets:June 30, 201336,27129,6391,364(990)66,284December 31, 201236,05729,1831,408(736)65,912Goodwill:June 30, 201319,6586,896——26,554December 31, 201219,6466,749——26,395(1)

    Net revenues of the Pharmacy Services Segment include approximately $2.0 billion and $2.1 billion of retail co-payments for the three months ended June 30, 2013 and 2012, respectively, as well as $4.2 billion and $4.4 billion of retail co-payments for the six months ended June 30, 2013 and 2012, respectively.(2)

    Intersegment eliminations relate to two types of transaction: (i) Intersegment revenues that occur when Pharmacy Services Segment customers use Retail Pharmacy Segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a standalone basis, and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services Segment customers, through the Company's intersegment activities (such as the Maintenance Choice program), elect to pick-up their maintenance prescriptions at Retail Pharmacy Segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis. The following amounts are eliminated in consolidation in connection with the item (ii) intersegment activity: net revenues of $1.1 billion and $840 million for the three months ended June 30, 2013 and 2012, respectively, and $2.0 billion and $1.6 billion for the six months ended June 30, 2013 and 2012, respectively; gross profit and operating profit of $127 million and $97 million for the three months ended June 30, 2013 and 2012, respectively, and $265 million and $172 million for the six months ended June 30, 2013 and 2012, respectively. Supplemental Information(Unaudited) Pharmacy Services SegmentThe following table summarizes the Pharmacy Services Segment's performance for the respective periods:Three Months EndedJune 30,Six Months EndedJune 30,In millions2013201220132012Net revenues$

    18,800$

    18,423$

    37,111$

    36,722Gross profit9637771,7311,393Gross profit % of net revenues5.1

    %4.2

    %4.7

    %3.8

    %Operating expenses288266557533Operating expense % of net revenues1.5

    %1.4

    %1.5

    %1.5

    %Operating profit6755111,174860Operating profit % of net revenues3.6

    %2.8

    %3.2

    %2.3

    %Net revenues(1):Mail choice(2)$

    6,036$

    5,744$

    11,905$

    11,410Pharmacy network(3)12,70912,62525,10025,209Other5554105103Pharmacy claims processed(1):Total226.6218.3454.3437.2Mail choice(2)20.720.541.340.9Pharmacy network(3)205.9197.8413.0396.3Generic dispensing rate(1):Total80.7

    %78.0

    %80.6

    %77.3

    %Mail choice(2)75.8

    %71.2

    %75.6

    %70.1

    %Pharmacy network(3)81.1

    %78.6

    %81.0

    %78.0

    %Mail choice penetration rate22.4

    %22.9

    %22.3

    %22.9

    %(1)

    Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice, which are included within the mail choice category.(2)

    Mail choice is defined as claims filled at a Pharmacy Services mail facility, which include specialty mail claims, as well as 90-day claims filled at retail under the Maintenance Choice program.(3)

    Pharmacy network is defined as claims filled at retail pharmacies, including our retail drugstores, but excluding Maintenance Choice activity. Supplemental Information(Unaudited)Retail Pharmacy SegmentThe following table summarizes the Retail Pharmacy Segment's performance for the respective periods:Three Months Ended June 30,Six Months EndedJune 30,In millions2013201220132012Net revenues$

    16,139$

    15,846$

    32,191$

    31,869Gross profit5,0004,7699,9529,341Gross profit % of net revenues31.0

    %30.1

    %30.9

    %29.3

    %Operating expenses3,4043,3006,8196,575Operating expense % of net revenues21.1

    %20.8

    %21.2

    %20.6

    %Operating profit1,5961,4693,1332,766Operating profit % of net revenues9.9

    %9.3

    %9.7

    %8.7

    %Retail prescriptions filled (90 Day = 1Rx)181.1176.4365.8355.9Retail prescriptions filled (90 Day = 3 Rx) (1)220.3208.5441.8418.5Net revenue increase:Total1.9

    %6.9

    %1.0

    %8.4

    %Pharmacy2.2

    %8.3

    %0.5

    %9.7

    %Front store1.1

    %3.9

    %2.1

    %5.5

    %Total prescription volume (90 Day = 1 Rx)2.6

    %8.7

    %2.8

    %8.5

    %Total prescription volume (90 Day = 3 Rx) (1)5.6

    %10.8

    %5.6

    %10.6

    %Same store increase (decrease):Total sales0.4

    %5.6

    %(0.4)%7.0

    %Pharmacy sales0.8

    %7.2

    %(0.8)%8.5

    %Front store sales(0.4)%2.3

    %0.5

    %3.7

    %Prescription volume (90 Day = 1 Rx)1.8

    %7.7

    %1.9

    %7.4

    %Prescription volume (90 Day = 3 Rx) (1)5.0

    %9.8

    %4.9

    %9.5

    %Generic dispensing rate81.9

    %79.1

    %81.6

    %78.6

    %Pharmacy % of total revenues69.1

    %68.8

    %69.0

    %69.4

    %Third party % of pharmacy revenue97.8

    %97.6

    %97.8

    %97.9

    (1)

    Includes the adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription. Adjusted Earnings Per Share Guidance(Unaudited)The following reconciliation of estimated income before income tax provision to estimated adjusted earnings per share contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2012 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-over-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.In millions, except per share amountsYear EndingDecember 31, 2013Income before income tax provision$

    7,347$

    7,476Amortization495495Adjusted income before income tax provision7,8427,971Adjusted income tax provision3,0543,111Adjusted income from continuing operations attributable to CVS Caremark$

    4,788$

    4,860Weighted average diluted common shares outstanding1,2291,227Adjusted earnings per share from continuing operations attributable to CVS Caremark$

    3.90$

    3.96Three Months EndingSeptember 30, 2013Income before income tax provision$

    1,888$

    1,942Amortization125125Adjusted income before income tax provision2,0132,067Adjusted income tax provision781800Adjusted income from continuing operations attributable to CVS Caremark$

    1,232$

    1,267Weighted average diluted common shares outstanding1,2341,233Adjusted earnings per share from continuing operations attributable to CVS Caremark$

    1.00$

    1.03 Free Cash Flow Guidance(Unaudited)The following reconciliation of net cash provided by operating activities to free cash flow contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2012 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-over-year cash flow performance by adjusting cash provided by operating activities, by capital expenditures and proceeds from sale-leaseback transactions.In millionsYear EndingDecember 31, 2013Net cash provided by operating activities$

    6,350$

    6,550Subtract: Additions to property and equipment(2,200)(2,000)Add: Proceeds from sale-leaseback transactions600500Free cash flow$

    4,750$

    5,050  


    '/>"/>
    SOURCE CVS Caremark Corporation
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
    2. CVS Caremark Reports Record First Quarter Results
    3. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
    4. CVS Caremark Research Identifies Positive Link Between Medication Adherence and Employee Productivity
    5. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
    6. CVS Caremark To Present At Goldman Sachs 2012 Global Retailing Conference
    7. CVS Caremark to Present at Morgan Stanley Global Healthcare Conference
    8. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
    9. CVS Caremark Donates More Than $100,000 to Hurricane Sandy Relief Efforts
    10. CVS Caremark To Present At Lazard Capital Markets 9th Annual Healthcare Conference
    11. CVS Caremark Reports Third Quarter Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/8/2016)... -- --> --> ... Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) ... Gynecology) - Global Forecasts to 2020", published by MarketsandMarkets, ... period of 2015 to 2020. The market is expected ... 10.5% from 2015 to 2020. Browse 73 ...
    (Date:2/8/2016)... , Feb. 8, 2016 ... of the "Global Skin Protective Equipment Market ... --> http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the ... Market 2016-2020" report to their offering. ... http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition of the ...
    (Date:2/8/2016)... SOUTHAMPTON, N.Y. , Feb. 8, 2016 In a historic ... support of plans to construct a medical cannabis cultivation facility and dispensary ... State of New York as a provider for patients ... of New York as a provider for patients in the ... (83) to 29% (34) to approve the project and pursue designation from ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... , ... February 08, 2016 , ... ... and clothing, announced expansion into Canada to provide its range of unique and ... sales office in Quebec City that will provide bilingual customer service and marketing ...
    (Date:2/8/2016)... ... 08, 2016 , ... Local insurance agency Dennis Fuller & ... has initiated a fundraiser for a two year old little girl named Bella, ... To support this beautiful child who is facing life’s journey without her loving ...
    (Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should ... Bentonite Clay” the health benefits of integrating clay into a daily diet are numerous, ... former motivational speaker, Perry A~ has since dedicated her life to learning about the ...
    (Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s ... booths and 700 companies. Attendees also get to see the most incredible gardens ... & Home Show , at the Colorado Convention Center - 700 14th St. Denver ...
    (Date:2/8/2016)... Overland Park, KS (PRWEB) , ... February 08, 2016 , ... ... Oils, a leader in Mole removal products. , Moles are derived from a cluster ... can appear in all the wrong places and create a lifetime of embarrassment. Historically, ...
    Breaking Medicine News(10 mins):